

10/552155

JC09 Rec'd PCT/PTO 11 OCT 2005

Practitioner's Docket No. 701826-57350


PATENT

IN THE UNITED STATES RECEIVING OFFICE

PCT/CA2003/000547	11.04.2003 11 April 2003	
International Application Number	International Filing Date	International Earliest Priority Date

TITLE OF INVENTION: METHODS FOR RELATIVE QUANTIFICATION OF
SPECIFIC NUCLEIC ACID SEQUENCES

APPLICANT(S) FOR EO/DO: DNA LANDMARKS INC.
INVENTOR(S)/APPLICANT(S) FOR US: LaFOREST, Martin et al.

CERTIFICATE OF MAILING
<p>I hereby certify that this correspondence, on the date shown below, is being deposited with the United States Postal Service with sufficient postage as Express Mail Label No. EV 653001534 US in an envelope addressed to MAIL STOP PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p> <p>Date: <u>October 11, 2005</u></p> <p align="right"> Linda M. Ginsberg</p>

MAIL STOP PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56, 1.97, and 1.98, Applicants wish to bring to the Examiner's attention the following references, References B1-B2 and C1-C7 cited in the attached Forms PTO/SB/08a and b.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

- X (1) within three (3) months of the Filing Date or **before the mailing date of the First Office Action** on the merits; or
- _____ (2) within three months of the mailing date of the PCT International Search Report; or

- _____ (3) after the period defined in (1) but before the mailing date of a **Final Rejection or Notice of Allowance**, and the requisite Certification or fee under Rule 1.17(p), namely **\$180.00**, is included herein; or
- _____ (4) after the mailing date of a **Final Rejection or Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.

 X A copy of the International Search Report is enclosed herewith.

It is respectfully requested that each of the documents shown on the attached form(s) PTO/SB/08a and b be made of record in this application.

Copies of these documents (CHECK ONE):

 X are enclosed herewith; or

_____ have been cited in the parent application, and are thus not being resubmitted herein.

FEE AUTHORIZATION

The Commissioner is authorized to charge fee deficiencies or credit overpayments associated with this submission to the NIXON PEABODY LLP Deposit Account No. 50-0850.

Date: October 11, 2005

Respectfully submitted,



David S. Resnick (Reg. No. 34,235)
NIXON PEABODY LLP
100 Summer Street
Boston, MA 02110-2131
(617) 345-6057

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

10/552155
 JC09 Rec'd PCT/PTO 11 OCT 2005

Substitute for form I449A/PTO				INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	
Application Number		371 of PCT/CA2003/000547			
I.A. Filing Date		11 April 2003			
First Named Inventor		Martin LaForest			
Art Unit		To be assigned			
Examiner Name		To be assigned			
Attorney Docket Number		701826-57350			
Sheet	2	of	2		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	ALDERBORN, A. et al.; Genome Research; 10(8):1249-1258 (08/2000)	
	C2	BERNARD, Philip S. et al.; Clinical Chemistry; 48(8):1178-1185 (08/2002)	
	C3	PIELBERG, G. et al.; Genetics; 160(1):305-311 (01/2002)	
	C4	PIELBERG, G. et al.; Genome Research; 13(9):2171-2177 (09/2003)	
	C5	QIU, P.J. et al.; Biochemical and Biophysical Research Communications; 309(2):331-338 (09/19/2003)	
	C6	REIS, P.P. et al.; Oncogene; 21(42):6480-6487 (09/19/2002)	
	C7	RONAGHI, M.; Genome Research; 11(1):3-11 (01/2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.